Physician profile
James Love
NPI 1073595310
$8,340.67
in general payments reported to CMS, 2019-2025
48 companies · $89.96 in 2025
The $89.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $844 · 2021: $1,552 · 2022: $1,759 · 2023: $2,465 · 2024: $225 · 2025: $89.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $815.34 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $771.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Astrazeneca Pharmaceuticals LP | $737.74 | 2019-2023 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.15 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $585.65 | 2019-2023 | |
| Novo Nordisk INC | $500.71 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $441.59 | 2019-2023 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $438.29 | 2019-2023 | Spravato, Xarelto |
| Abbvie INC. | $388.73 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $273.88 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $270.18 | 2019-2023 | |
| Astellas Pharma US INC | $265.81 | 2019-2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $247.53 | 2019-2025 | Eohilia |
| Idorsia Pharmaceuticals US INC | $212.59 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $196.51 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.